Human immunodeficiency virus in pregnant women. The importance of recognizing the infection during pregnancy and risk factors for perinatal transmission;Infección por virus de inmunodeficiencia humana en la embarazada. Importancia del conocimiento de la infección en el embarazo y factores de riesgo en la transmisión perinatal

Revista Medica de Chile

Volumn 131, Issue 6, 2003, Pages 633-640

  Ovalle S , Alfredo ^a,b   Vizueta R , Eloísa ^b   Casals C , Alejandro ^a   Northland A , Rebeca ^c   Reinaldo Gonzalez R ^a   Eduardo Labbe M ^d  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^c Arriaran Foundation   (Chile)

^d NONE

Author keywords

Hiv infections; Hiv seropositivity; Infections; Perinatal care; Pregnancy complications

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; BREAST FEEDING; CESAREAN SECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE TRANSMISSION; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PERINATAL INFECTION; PREGNANCY; VAGINAL DELIVERY; VERTICAL TRANSMISSION;

ADULT; ANTI-HIV AGENTS; CHILE; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; ZIDOVUDINE;

EID: 12344329201     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. CHÁVEZ A, ALVAREZ AM, WU E, VIZUETA E. Transmisión vertical de la infección por virus de inmunodeficiencia humana: Impacto de la aplicación del protocolo ACTG 076 en Chile. Rev Chil Infect 2000; 17: 297-301.
2. CHÁVEZ A, VIZUETA E, ALVAREZ AM, PEÑA AM, LARRAÑAGA, WU E. Situación actual de la infección por virus de inmunodeficiencia humana en niños. Rev Chil Infect 2001; 18: 271-4.
3. LANDESMAN SH, KALISH LA, BURNS DN, MINKOFF H, FOX HE, ZORRILLA C ET AL. Obstetrical factors and the transmission of the human inmunodeficiency virus type 1 from mother to child. N Engl J Med 1996; 334: 1617-23.
4. THOMAS PA, WEEDON J, KRASINSKI K, ABRAMS E, SHAFFER N, MATHESON P ET AL. Maternal predictors of perinatal human immunodeficiency virus transmission. Pediatr Infect Dis J 1994; 13: 489-95.
5. OVALLE A, CASALS A, DABANCH J, VIZUETA E, WOLFF M, NORTHLAND R ET AL. Infección por VIH y embarazo. Rev Chil Obstet Ginecol 1998; 63: 73-8.
6. COOPER ER, CHARURAT M, BURNS DN, BLATTNER W, HOFF R. Trends in antiretroviral therapy and mother-infant transmission of HIV. J Acquir Immune Defic Syndr 2000; 24: 45-7.
7. EUROPEAN COLLABORATIVE STUDY. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 2001; 15: 761-70.
8. MORRIS AB, CU-UVIN S, HARWELL JI, GARB J, ZORRILLA C, VAJARANANT M ET AL. Multicenter review of protease inhibitors in 89 pregnancies. J Acquir Immune Defic Syndr 2000; 25: 306-11.
9. MANDELBROT L, LANDREAU-MASCARO A, REKACEWICZ C, BERREBI A, BENIFLA JL, BURGARD M ET AL. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-93.
10. TUOMALA RE, SHAPIRO DE, MOFENSON LM, BRYSON Y, CULNANE M, HUGHES MD ET AL. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346: 1803-70.
11. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998; 47: 1-30. [Erratum, MMWR Morb Mortal Wkly Rep 1998; 47: 287, 315].
12. OVALLE A, MARTÍNEZ MA, GÓMEZ R, SÁEZ J, MENARES I, ASPILLAGA C ET AL. Parto prematuro con membranas intactas. Microbiología del líquido amniótico y tracto genital inferior y su relación con los resultados maternoneonatales. Rev Méd Chile 2000; 128: 985-95.
13. JUEZ G, LUCERO E, VENTURA-JUNCA P, GONZÁLEZ H, TAPIA JL, WINTER A. Crecimiento intrauterino en recién nacidos chilenos de clase media. Rev Chil Pediatr 1989; 60: 198-202.
14. Centers for Disease Control and Prevention Atlanta (CDC). MMWR 1992; 41: 1-19.
15. Centers for Disease Control and Prevention Atlanta (CDC). MMWR 1994; 43: 1-10.
16. a edición 1991; 1262.
17. OVALLE A, GONZÁLEZ P, ROA J, MARÍN J. Infecciones genitourinarias y cerclaje en el aborto espontáneo de segundo trimestre y parto prematuro recurrente. Rev Chil Obstet Ginecol 1988; 53: 162-8.
18. LUMBIGANON P, PIAGGIO G, VILLAR J, PINOL A, BAKKETEIG L, BERGSJO P ET AL. The epidemiology of syphilis in pregnancy. Int J STD AIDS 2002; 13: 486-94.
19. OYARZÚN E. Alto Riesgo Obstétrico. Edic Universidad Católica de Chile 1997; 231-8.
20. WINER N. Management of threatening preterm labor with intact membranes: indications for antibiotics. J Gynecol Obstet Biol Reprod 2002; 31 (7 Suppl): 5S74-83.
21. HANSON IC, ANTONELLI TA, SPERLING RS, OLESKE JM, COOPER E, CULNANE M ET AL. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 463-7.
22. CONNOR EM, SPERLING RS, GELBER R, KISELEV P, SCOTT G, O'SULLIVAN MJ ET AL. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-80.
23. SPERLING RS, SHAPIRO DE, MCSHERRY GD, BRITTO P, CUNNINGHAM BE, CULNANE M ET AL. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998; 12: 1805-13.
24. WHITE A, ELDRIDGE R, ANDREWS E. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. Acta Paediatr Suppl 1997; 421: 86-8.
25. BLANCHE S, TARDIEU M, RUSTIN P, SLAMA A, BARRET B, FIRTION G ET AL. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-9.
26. GUAY LA, MUSOKE P, FLEMING T, BAGENDA D, ALLEN M, NAKABIITO C ET AL. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother to child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999; 354: 795-802.
27. VISNEGARWALA F, KRAUSE KL, MUSHER DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997; 127: 947.
28. EASTONE JA, DECKER CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997; 127: 948.
29. DUBE M. Metabolic complications of antiretroviral therapies. AIDS Clinical Care 1998; 10: 41-8.